Low FOXA1 expression predicts good response to neo-adjuvant chemotherapy resulting in good outcomes for luminal HER2-negative breast cancer cases

BACKGROUND: FOXA1 expression is a good prognostic marker for endocrine therapy in hormone-positive breast cancer. We retrospectively examined breast cancer patients with luminal human epidermal growth factor receptor 2 (HER2)-negative tumours, as defined by immunohistochemistry, who received neo-adj...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Br J Cancer
Hlavní autoři: Horimoto, Y, Arakawa, A, Harada-Shoji, N, Sonoue, H, Yoshida, Y, Himuro, T, Igari, F, Tokuda, E, Mamat, O, Tanabe, M, Hino, O, Saito, M
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group 2015
Témata:
Translational Therapeutics
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4453454/
https://ncbi.nlm.nih.gov/pubmed/25422910
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2014.595
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky